81
Participants
Start Date
April 30, 2010
Primary Completion Date
December 31, 2013
Study Completion Date
April 30, 2016
ADXS11-001 (Lm-LLO-E7)
ADXS11-001 at one of three dose levels given as 3 vaccinations separated by 4 weeks with an oral antibiotic regimen subsequent to dosing.
Placebo Control
3 intravenous infusions of normal saline at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
New York Downtown Hospital, New York
Montefiore Medical Center, The Bronx
Temple University, Philadelphia
Altus Research, Lake Worth
Visions Clinical Research, Boynton Beach
Indiana University Dept. of OB/GYN Oncology, Indianapolis
Center for Women, Chicago
InVisions Consultants, LLC- c/o Institute for Women's Health, San Antonio
InVisions Consultants, LLC, San Antonio
Wasatch Clinical Research, Salt Lake City
Arizona OB/GYN Affiliates, PC, Phoenix
Precision Trials, Phoenix
New Horizons Women's Care, LLC, Chandler
Visions Clinical Research - Tucson, Tucson
Grossmont Center for Clinical Research, La Mesa
Lead Sponsor
Advaxis, Inc.
INDUSTRY